Vice Chairman of Changsheng Bio was sued by Industrial Securities, involving 630 million yuan
Medical Network August 7th Recently, the longevity biological vaccine incident continued to ferment, the risk is affecting the securities dealers of large shareholders pledge stocks.
Industrial Securities, which was deeply mired in ST Changsheng’s equity pledge crisis, announced on August 6 that it had sued Zhang Haohao, the vice chairman of Changsheng Biological, and Zhang Wei’s related matters.
According to the announcement, the names of the parties in the lawsuit or arbitration are Zhang Yihao, Zhang Wei, and the relationship between the parties and the company is the client. The litigation/arbitration is handled on August 1, and the litigation/arbitration case is a pledged securities repurchase dispute. The principal is 630 million yuan, and the institution that files / accepts the arbitration is the Higher People's Court of Fujian Province.
The data shows that ST Changsheng's current equity pledge is 250 million shares, the equity pledge rate is 25.69%, and the proportion of circulating A shares is 61.97%. Among them, most of the pledge of pledge shares is Industrial Securities.
In the secondary market, after the exposure of the problem vaccine event (since July 16), ST Changsheng (from the opening of the market on July 26, 2018, the name of 'Changsheng Bio' is changed to 'ST Changsheng') 15 trading days limit.
On July 23, ST Changsheng announced that the company's shareholder Zhang Yihao had three supplementary pledges for the 73.362 million shares he held, and the pledgee was all Xingye Securities. On the same day, the Shenzhen Stock Exchange issued an announcement saying that for the majority shareholder of Changsheng Bio, The shares held by Dong Jiangao are subject to restricted sales, which means that even if the stock falls below the closing line, it cannot be forced.
On July 24, Industrial Securities announced that the initial transaction amount of the two major shareholders of Changsheng Bio, Wei Chen and Zhang Yihao, was RMB 0.45 billion and RMB 630 million respectively; the number of pledged shares was RMB 11 million and 167 million shares respectively. The performance guarantee ratios were 277% and 307% respectively. Yichen Pan and Zhang Yihao collectively plucked 178 million shares of Changsheng Biological, with a purchase amount of 675 million yuan.
At the time, Industrial Securities said that in view of the fact that Changsheng Bio has been investigated by the State Food and Drug Administration and the China Securities Regulatory Commission, the Shenzhen Stock Exchange has imposed restrictions on the shares held by Changsheng Bio-large shareholders and Dong Jiangao. The company will track developments in real time and evaluate the company's operations in a timely manner. The impact and response.
ST Changsheng faces great risk of delisting. On the evening of July 27, the CSRC announced the revision of the delisting system: The listed company constitutes a major violation of the law in the security field, fraudulent issuance, and major information disclosure is illegal, and a mandatory delisting system is implemented. This is the market. It is believed to be a strong signal that ST will be delisted.
